Visian Toric Implantable Collamer Lens (TICL)
STAAR Surgical Company · Decision date Dec 10, 2025
What did the FDA approve?
FDA records P030016/S049 as a supplement to PMA P030016, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Dec 10, 2025.
FDA approval order statement
Approval for updates to labeling for the Visian Toric Implantable Collamer Lens (TICL), EVO/EVO+ Visian ICL, and EVO/EVO+ Visian TICL to reflect the findings of the P030016/S001 PMA New Enrollment Post-Approval Study.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Ophthalmic
- Decision date
- Dec 10, 2025
- FDA change category
- Labeling Change - PAS
Regulatory record facts
- Identifier
- P030016/S049
- Regulatory pathway
- PMA supplement
- Applicant
- STAAR Surgical Company
- Product code
- QCB
- Decision code
- APPR
- Decision date
- Dec 10, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Phakic toric intraocular lens.
- Applicant
- STAAR Surgical Company
- Product code
- QCB
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P030016/S049 received
Application receipt date recorded by FDA.
P030016/S048 · Related supplement
VISIAN ICL (IMPLANTABLE COLLAMER LENS)
P030016/S049 · FDA decision
Normal 180 Day Track No User Fee
P030016/S051 · Related supplement
The EVO/EVO+ Visian Implantable Collamer Lens (ICL)
Timeline entries are records held by MedtechLedger for P030016. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P030016
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
VISIAN ICL (IMPLANTABLE COLLAMER LENS)P030016/S048 | STAAR Surgical Company | PMA supplement | Nov 14, 2025 | FDA |
| STAAR Surgical Company | PMA supplement | Mar 4, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
STAAR Surgical Company
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1911 Walker Ave., Monrovia, CA, 91016
Sources and methodology
- Original FDA record: P030016/S049
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records